Panitumumab is a for the treatment of metastatic colorectal cancer.
It is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR) and is an antineoplastic agent.
It is administered through intravenous infusion every 2 weeks.
In 2016, it sold €100 million in Europe.
It has an immunogenicity rate of 2%.
Labs that test for drug level: